Chemical analysis of synthetic cannabinoids as designer drugs in herbal products
Introduction
Cannabis sativa L. (cannabis, marijuana) is widely abused throughout the world because it contains psychoactive cannabinoids such as Δ9-tetrahydrocannabinol. In Japan, the abuse of cannabis has recently increased, along with the abuse of a number of herbal products that are also distributed on the drug market for their cannabis-like effects when smoked. Although the active components of these herbal products were not identified, we recently found two synthetic cannabinoids as adulterants in herbal products that had been sold commercially as incense. One was (1RS,3SR)-3-[2-hydroxy-4-(2-methylnonan-2-yl)phenyl]cyclohexan-1-ol (cannabicyclohexanol, 1), which was detected together with its trans-diastereomer (2) [1]; the other was 1-naphthalenyl(1-pentyl-1H-indol-3-yl)methanone (JWH-018, 3) [2] (Fig. 1). Compound 1, which is a non-classical cannabinoid, was first synthesized by Pfizer Inc. in 1979 [3] and reported as a potent cannabinoid analog in the 1990s [4], [5], [6], [7], [8]. In consideration of its general properties, this compound was renamed cannabicyclohexanol with the agreement of Pfizer Inc. Compound 3, which is an aminoalkyl naphthoyl indole derivative, was first synthesized by Huffman et al. in 1998 and reported as a potent cannabinoid receptor agonist possessing in vivo pharmacological cannabinoid analog activity [9], [10], [11], [12]. Auwärter et al. also reported the identification of these compounds from some herbal products around the same time [13]. In January 2009, Germany's Health Minister announced that compounds 1 and 3 and their homologs had been identified as active components in a mislabeled mixture of herbs. Control of these compounds was begun in Germany immediately thereafter (on 22 January 2009) [14]; Austria, France and other countries initiated legal actions to ban or otherwise control these synthetic cannabinoids over the preceding months [15].
In this study, we report the analysis and identification of several synthetic cannabinoids as adulterants in herbal products using gas chromatography–mass spectrometry (GC-MS) and liquid chromatography–mass spectrometry (LC-MS). In addition, the results of a survey of herbal products being sold on the Japanese market are described.
Section snippets
Chemicals and reagents
HPLC-grade acetonitrile, betamethasone valerate (internal standard, IS) and α-tocopherol were obtained from Wako Pure Chemical Industries, Ltd. (Osaka, Japan). Authentic cannabicyclohexanol (1) and JWH-018 (3) were isolated from herbal products and identified in our previous studies [1], [2]. Oleamide (4) was purchased from Tokyo Chemical Industry Co., Ltd. (Tokyo, Japan). CP-47,497 (5) and JWH-073 (6) were purchased from Cayman Chemical (Ann Arbor, MI). All other common chemicals and solvents
Analyses of herbal products obtained from the Japanese market
Forty-six herbal products currently being sold in Japan for their expected cannabis-like effects were purchased via the Internet. These products appeared in primarily two forms i.e., as bits of dried leaves or as cigarettes (Table 1).
GC-MS and LC-MS analyses indicated that most of the products contained the two major compounds (1 and 3) (Fig. 1, Fig. 2a–p) and these compounds were reported in our previous studies [1], [2]. Oleamide (cis-9,10-octadecenoamide, 4), which shows cannabinoid-like
Discussion
Compound 1 has been reported as a cannabimimetic agent that produces more potent effects than those of typical cannabinoids such as Δ9-tetrahydrocannabinol (Δ9-THC). Compton et al. reported that compound 1 showed an 8.5-fold more potent affinity for the CB receptor (Ki = 4.7 nM) and 5 had a 4.3-fold more potent affinity for the CB receptor (Ki = 9.5 nM) than did Δ9-THC (Ki = 40.7 nM) [4]. Additionally, they reported that compounds 1 and 5 were approximately 5-fold and 2-fold more potent than Δ9-THC,
Acknowledgment
Part of this work was supported by a Health and Labor Sciences Research Grant from the Ministry of Health, Labour, and Welfare, Japan.
References (29)
- et al.
Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs
Pharmacol. Biochem. Behav.
(1991) - et al.
Influence of the N-1 alkyl chain length of cannabimimetic indoles upon CB1 and CB2 receptor binding
Drug Alcohol Depend.
(2000) - et al.
3-Indolyl-1-naphthylmethanes: new cannabimimetic indoles provide evidence for aromatic stacking interactions with the CB1 cannabinoid receptor
Bioorg. Med. Chem.
(2003) - et al.
Prototype cannabinoid analgetics, prostaglandins and opiates—a search for points of mechanistic interaction
Life Sci.
(1982) - et al.
Design, synthesis and pharmacology of cannabimimetic indoles
Bioorg. Med. Chem. Lett.
(1994) - et al.
Identification of a cannabinoid analog as a new type of designer drug in a herbal product
Chem. Pharm. Bull.
(2009) - et al.
Identification of a cannabimimetic indole as a designer drug in a herbal product
Forensic Toxicol.
(2009) - C.A. Harbert, M.R. Johnson, L.S.Jr. Melvin, 3-[Hydroxy-4-(substituted)-phenyl]-cycloalkanone and cycloalkanol...
- et al.
Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities
J. Pharmacol. Exp. Ther.
(1993) - et al.
Pharmacological profile of a series of bicyclic cannabinoid analogs: classification as cannabimimetic agents
J. Pharmacol. Exp. Ther.
(1992)
Structure-activity relationships for cannabinoid receptor-binding and analgesic activity: studies of bicyclic cannabinoid analogs
Mol. Pharmacol.
Characterization of the lipophilicity of natural and synthetic analogs of delta 9-tetrahydrocannabinol and its relationship to pharmacological potency
J. Pharmacol. Exp. Ther.
Structure-activity relationships of indole- and pyrrole-derived cannabinoids
J. Pharmacol. Exp. Ther.
Cannabimimetic indoles, pyrroles and indenes
Curr. Med. Chem.
Cited by (216)
Identification of a novel bromoindazole synthetic cannabinoid analogue in seized e-cigarette liquid: ADB-BRINACA
2022, Forensic Science InternationalDoes cannabis testing in the military drive synthetic cannabinoid use? Self-reported use motivations among justice-involved veterans
2022, International Journal of Drug PolicyMicellar electrokinetic chromatography method for the analysis of synthetic and phytocannabinoids
2022, Journal of Chromatography ACitation Excerpt :The performance characteristics of the method are given in Table 5. The concentrations of different SCs in distributed products are highly varied, ranging from 1 to 340 mg/g [17,44,45]. According to UNODC, a method for the analysis of SCs should be able to detect concentrations of 1 to 30 mg/g [20].
Analytical Methods for Herbal Products Containing Synthetic Cannabinoids: A Review
2022, Forensic Chemistry